Markku Jalkanen

Markku Jalkanen serves as CEO at Faron. Faron operates in the pharmaceuticals sector with approximately 49.0 employees. The company is headquartered in Turku. Faron generates annual revenue of 857000.0.

Industry & Role Insights

• • MessageCEO tracks 1,288 executives in the pharmaceuticals sector.
• • We have verified contacts for 2 executives at Faron.
• • Our database includes 201,469 c suite-level executives.

MailJet Sendgrid Outlook Drupal Mobile Friendly YouTube WordPress.org Google Analytics Google Tag Manager Nginx

drug discovery drug development pharmaceuticals novel treatments for medical conditions with significant unmet needs ards acute respiratory distress syndrome cancer immunotherapy biopharmaceutical pharmaceutical manufacturing immunotherapy cancer treatment clinical trials phase i/ii bexmarilimab anti-clever-1 antibody hematological cancers solid tumors macrophage-targeting precision medicine treatment resistance oncology research patient outcomes research & development therapy combinations novel therapies drug candidates scientific advisory board bioinformatics market analysis financial reports investment strategy risk management clinical efficacy immune system patient-centered care biotech investment healthcare innovation pharmaceutical pipeline biotech research neoplasms novel combination therapies drug efficacy patient engagement sustainability in healthcare clinical development cancer research financial analysis peer-reviewed studies drug commercialization healthcare investment biopharma immuno-oncology market growth 9% r&d expenses aim listing investor relations medical health care health wellness & fitness hospital & health care information technology & services biotechnology

RH

Ralph Hughes Chief Business Officer at Faron

YM

Yathendra Madineni Chief Executive Officer at 4C Pharma Solutions

RB

Ronan Brown Chief Operating Officer at 4G Clinical

HK

Hitoshi Kamiya Chief Executive Officer at A2 Healthcare Corporation

LJ

Lars Jensen CEO at A-apoteket

Outreach Guidance — pharmaceuticals Sector

Executives like Markku Jalkanen in the pharmaceuticals sector receive targeted outreach from sales teams, recruiters, and investors. To stand out, personalize your message with industry-specific context and a clear, specific value proposition relevant to their role at Faron.

Markku Jalkanen's Position in the MessageCEO Database

• •Markku Jalkanen is 1 of 2 verified executive contacts we track at Faron.
• •1,240 verified executive contacts in pharmaceuticals are in the MessageCEO database.
• •9 verified contacts work at pharmaceuticals companies in the 49.0 employee range (same size as Faron).

Executive contact data compiled from public business filings, LinkedIn public profiles, company press materials, and verified outbound email testing. We do not publish personal addresses or sensitive identifiers. Methodology & sources · Removal requests handled at /remove-info · Updated June 2026.

How do I reach Markku Jalkanen directly?

Markku Jalkanen's verified email address is available to MessageCEO Pro subscribers. They currently serve as CEO at Faron. Access direct contact info to skip gatekeepers and reach the decision maker.

What company does Markku Jalkanen work for?

Markku Jalkanen is CEO at Faron, a company in the pharmaceuticals sector with 49.0 employees. The company is based in Turku.

Can I pitch or sell to Markku Jalkanen?

As CEO at Faron, Markku Jalkanen is a key decision-maker in the pharmaceuticals sector. MessageCEO Pro gives you verified email to reach Markku Jalkanen directly — ideal for B2B sales, partnerships, and executive recruiting.

What industry is Markku Jalkanen in?

Markku Jalkanen works in the pharmaceuticals industry as CEO at Faron. MessageCEO provides verified contact information for executives across all major industries.

Is Markku Jalkanen's contact information verified?

Yes. MessageCEO verifies executive contact information through multiple data sources and regular validation checks. Markku Jalkanen's profile is kept up-to-date with the latest available information.

Last updated: June 19, 2026